218 related articles for article (PubMed ID: 20521156)
1. Activity of doripenem against extended-spectrum beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa isolates.
Betriu C; Gómez M; López-Fabal F; Culebras E; Rodríguez-Avial I; Picazo JJ
Eur J Clin Microbiol Infect Dis; 2010 Sep; 29(9):1179-81. PubMed ID: 20521156
[TBL] [Abstract][Full Text] [Related]
2. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
Castanheira M; Duncan LR; Mendes RE; Sader HS; Shortridge D
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073
[TBL] [Abstract][Full Text] [Related]
3. Occurrence of PER-1 producing clinical isolates of Pseudomonas aeruginosa in Japan and their susceptibility to doripenem.
Yamano Y; Nishikawa T; Fujimura T; Yutsudou T; Tsuji M; Miwa H
J Antibiot (Tokyo); 2006 Dec; 59(12):791-6. PubMed ID: 17323646
[TBL] [Abstract][Full Text] [Related]
4. Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamases.
Mushtaq S; Ge Y; Livermore DM
Antimicrob Agents Chemother; 2004 Apr; 48(4):1313-9. PubMed ID: 15047535
[TBL] [Abstract][Full Text] [Related]
5. Doripenem activity tested against a global collection of Enterobacteriaceae, including isolates resistant to other extended-spectrum agents.
Mendes RE; Rhomberg PR; Bell JM; Turnidge JD; Sader HS
Diagn Microbiol Infect Dis; 2009 Apr; 63(4):415-25. PubMed ID: 19249175
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
Pillar CM; Torres MK; Brown NP; Shah D; Sahm DF
Antimicrob Agents Chemother; 2008 Dec; 52(12):4388-99. PubMed ID: 18779357
[TBL] [Abstract][Full Text] [Related]
7. Susceptibility of Pseudomonas aeruginosa clinical isolates in Japan to doripenem and other antipseudomonal agents.
Fujimura T; Anan N; Sugimori G; Watanabe T; Jinushi Y; Yoshida I; Yamano Y
Int J Antimicrob Agents; 2009 Dec; 34(6):523-8. PubMed ID: 19748767
[TBL] [Abstract][Full Text] [Related]
8. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
Vidaillac C; Leonard SN; Sader HS; Jones RN; Rybak MJ
Antimicrob Agents Chemother; 2009 Jun; 53(6):2360-6. PubMed ID: 19349512
[TBL] [Abstract][Full Text] [Related]
10. Comparative Activity of Carbapenem Testing (COMPACT) study in Germany.
Valenza G; Seifert H; Decker-Burgard S; Laeuffer J; Morrissey I; Mutters R;
Int J Antimicrob Agents; 2012 Mar; 39(3):255-8. PubMed ID: 22230334
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09.
Davies TA; Marie Queenan A; Morrow BJ; Shang W; Amsler K; He W; Lynch AS; Pillar C; Flamm RK
J Antimicrob Chemother; 2011 Oct; 66(10):2298-307. PubMed ID: 21775338
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial susceptibility of pathogens isolated from patients with complicated intra-abdominal infections at five medical centers in Taiwan that continuously participated in the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2006 to 2010.
Lee YL; Chen YS; Toh HS; Huang CC; Liu YM; Ho CM; Lu PL; Ko WC; Chen YH; Wang JH; Tang HJ; Yu KW; Liu YC; Chuang YC; Liu CE; Hsueh PR
Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S29-36. PubMed ID: 22749056
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial susceptibility of common pathogens isolated from postoperative intra-abdominal infections in Japan.
Takesue Y; Kusachi S; Mikamo H; Sato J; Watanabe A; Kiyota H; Iwata S; Kaku M; Hanaki H; Sumiyama Y; Kitagawa Y; Nakajima K; Ueda T; Uchino M; Mizuguchi T; Ambo Y; Konosu M; Ishibashi K; Matsuda A; Hase K; Harihara Y; Okabayashi K; Seki S; Hara T; Matsui K; Matsuo Y; Kobayashi M; Kubo S; Uchiyama K; Shimizu J; Kawabata R; Ohge H; Akagi S; Oka M; Wakatsuki T; Suzuki K; Okamoto K; Yanagihara K
J Infect Chemother; 2018 May; 24(5):330-340. PubMed ID: 29555391
[TBL] [Abstract][Full Text] [Related]
14. [Carbapenem resistance in ESBL positive Enterobacteriaceae isolates causing invasive infections].
Eser OK; Altun Uludağ H; Ergin A; Boral B; Sener B; Hasçelik G
Mikrobiyol Bul; 2014 Jan; 48(1):59-69. PubMed ID: 24506716
[TBL] [Abstract][Full Text] [Related]
15. In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactamase-producing clinical isolates.
Meletiadis J; Paranos P; Georgiou PC; Vourli S; Antonopoulou S; Michelaki A; Vagiakou E; Pournaras S
Int J Antimicrob Agents; 2021 Nov; 58(5):106440. PubMed ID: 34551356
[TBL] [Abstract][Full Text] [Related]
16. In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.
Hu YF; Liu CP; Wang NY; Shih SC
BMC Infect Dis; 2016 Aug; 16(1):444. PubMed ID: 27553962
[TBL] [Abstract][Full Text] [Related]
17. WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases.
Mushtaq S; Vickers A; Woodford N; Livermore DM
J Antimicrob Chemother; 2017 Jun; 72(6):1688-1695. PubMed ID: 28333319
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and antimicrobial susceptibility pattern of extended-spectrum beta-lactamase-producing Enterobacteriaceae in the United Arab Emirates.
Al-Zarouni M; Senok A; Rashid F; Al-Jesmi SM; Panigrahi D
Med Princ Pract; 2008; 17(1):32-6. PubMed ID: 18059098
[TBL] [Abstract][Full Text] [Related]
19. Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies.
Kaniga K; Flamm R; Tong SY; Lee M; Friedland I; Redman R
Antimicrob Agents Chemother; 2010 May; 54(5):2119-24. PubMed ID: 20211892
[TBL] [Abstract][Full Text] [Related]
20. [Comparative evaluation of in vitro activities of carbapenems against gram-negative pathogens: Turkish data of COMPACT study].
Korten V; Söyletir G; Yalçın AN; Oğünç D; Dokuzoğuz B; Esener H; Ulusoy S; Tünger A; Aygen B; Sümerkan B; Arman D; Dizbay M; Akova M; Hasçelik G; Eraksoy H; Başaran S; Köksal I; Bayramoğlu G; Akalın H; Sınırtaş M
Mikrobiyol Bul; 2011 Apr; 45(2):197-209. PubMed ID: 21644063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
